Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]
Intern Med JAnderson MA +9 more
europepmc +1 more source
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures". [PDF]
ACS Pharmacol Transl SciDarragh AC +5 more
europepmc +2 more sources
Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]
MoleculesYe Q, Ma S.
europepmc +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]
ChemMedChemAlmodóvar-Rivera CM +5 more
europepmc +1 more source
Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. [PDF]
Cancer MedObeng-Kusi M +10 more
europepmc +1 more source
Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]
CureusPradhan A, Panchal HP.
europepmc +1 more source
Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage. [PDF]
TheranosticsHao H +14 more
europepmc +1 more source